Neurodegenerative Diseases Related Content

Research has found that low-intensity transcranial ultrasound stimulation can modulate brain activity and behaviours, supporting the observations of psychiatric conditions.

Professor Olivier Braissant, believes there is hope for the treatment of creatine deficiency thanks to new genetic disease research - here, he tells us all about the recent developments.

A very warm welcome to the Winter volume of North America Analysis: In our health & social care section, Dr Eduardo Bianco, Chair of the Tobacco Expert Group at the World Heart Federation discusses the ongoing battle to end the tobacco epidemic and how e-cigarettes may be part of the problem.

The study found that expectations of how painful something will be, actually changes how the pain feels.

A new study finds the exact molecular mechanism that turns acute pain into chronic pain - a condition that leads to the use of opioids and often, lifelong addiction.

The study, published in PLoS Biology, looked at the neurotransmitter in the brain that calculates whether to pursue a task - in other words, motivation.

Dr Lynn Woods, Professor in the Department of Doctoral Programs, School of Nursing, Azusa Pacific University, describes Latinx with dementia and in this respect, why culture matters.

Here, we discover the impact and importance of psychedelic medicine through the eyes of Amanda Feilding, Director of The Beckley Foundation.

Professor Mogens Hørder, PPI expert, JPND’s management board member and representative of member state Denmark, discusses how Patient and Public Involvement (PPI) is at the heart of neurodegenerative disease research.

Chief Executive of the Huntington’s Disease Association, Cath Stanley, maps out the charities ongoing work to support its community, despite the COVID-19 pandemic.

Nina Schor, Deputy Director and Acting Scientific Director of NINDS, underlines the importance of investing in the future of neuroscience.

A new study by the University of Eastern Finland finds that a blood test could help to diagnose patients with frontotemporal dementia.

Indiana University School of Medicine researchers are attempting to use magnetic nanoparticles to develop a cure for neurological disorders from epilepsy to Alzheimer's - without any invasive or genetic treatment.

Dr Rutger Zietsma – CEO at Manus Neurodynamica Ltd – and PD Dr Angela Deutschländer share their vision on earlier diagnosis and objective symptom tracking with the NeuroMotor PenTM.

Professor of Neurology Thomas Gasser, JPND’s Scientific Advisory Board Chair and Director of the Department of Neurodegenerative Diseases, shares in an interview JPND’s innovative research and collaboration efforts in the universal race against Alzheimer’s and Parkinson’s diseases.

Dr Roderick Corriveau, PhD from the National Institute of Neurological Disorders & Stroke, part of the National Institutes of Health in the U.S., details the importance of understanding the many possible paths to dementia.

Doctors Osama Al Dalahmah and James E. Goldman discuss their work on single Nuclei RNA sequencing of Huntington’s disease brain tissues.

Here, Professor Pamela Lein at University of California, Davis, discusses the relatively unexplored issue of the human brain as a target of COVID-19.

Dr. James E Goldman and Dr. Osama Al-Dalahmah from the Department of Pathology and Cell Biology at Columbia University, provide an in-depth perspective on Huntington’s disease (HD) research.

Dr Timothy Kwok, Professor at The Chinese University of Hong Kong, shares the development of the Electronic Cognitive Screen (EC-Screen) for population screening of dementia in older people.